How India Exports Nicotine to the World

Nicotine replacement therapies (NRTs), such as nicotine polacrilex gum and lozenges, have been approved by the U.S. Food and Drug Administration (FDA) through both New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs). For instance, Circa Pharmaceuticals, Inc. received approval for Nicotine Polacrilex Gum USP under NDA 74-707 on March 19, 1999. Additionally, GlaxoSmithKline's Nicotine Polacrilex Lozenge, marketed as Commit, was approved under NDA 21-330 on October 31, 2002. These approvals indicate a well-established regulatory pathway for nicotine-containing products in the U.S. market.

The substantial export of nicotine products from India to the United States, accounting for 90.1% of total exports, underscores the importance of compliance with FDA regulations. With 61 active Indian exporters and a repeat buyer rate of 78.0%, maintaining adherence to FDA standards is crucial for market access and sustained business relationships.

In the European Union, nicotine-containing products intended for smoking cessation require marketing authorization from the European Medicines Agency (EMA). For example, Champix (varenicline) was granted marketing authorization on September 26, 2006. (ema.europa.eu) Manufacturers must comply with EU Good Manufacturing Practice (GMP) requirements to ensure product quality and safety.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the licensing of nicotine-containing products. The MHRA provides guidance on licensing procedures for electronic cigarettes and other inhaled nicotine-containing products as medicines. (gov.uk) Compliance with these regulatory frameworks is essential for Indian exporters targeting the EU and UK markets.

Nicotine replacement therapies are included in the World Health Organization's (WHO) Model List of Essential Medicines, recognizing their importance in public health. These products must meet international pharmacopoeia standards, such as those outlined in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure consistent quality and efficacy.

In India, nicotine-containing products are regulated by the Central Drugs Standard Control Organization (CDSCO). These products are typically classified under Schedule H, indicating that they require a prescription for sale. The National Pharmaceutical Pricing Authority (NPPA) monitors the pricing of essential medicines; however, as of March 2026, there is no specific ceiling price set for nicotine replacement therapies. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) to comply with export regulations.

The primary patents for many nicotine replacement therapies have expired, leading to increased generic competition. This competitive landscape offers opportunities for Indian exporters to supply cost-effective alternatives to global markets.

In February 2026, Essex Trading Standards in the UK prosecuted three retailers for selling nicotine inhaling products to individuals under 18, highlighting stringent enforcement of age restrictions. (essex.gov.uk) Similarly, in February 2026, a Derbyshire business was fined for selling vapes to underage persons and possessing non-compliant vapes, emphasizing the importance of regulatory compliance in the UK market. (derbyshire.gov.uk)

These developments underscore the necessity for Indian exporters to stay informed about regulatory changes and enforcement actions in key markets to ensure compliance and maintain market access.

India's pharmaceutical industry, including nicotine production, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these essential components are sourced from Chinese manufacturers, underscoring a significant dependency. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and logistical disruptions between the two nations.

Recent events have further highlighted this vulnerability. In March 2026, the closure of the Strait of Hormuz disrupted global supply chains, affecting the transportation of critical raw materials. This blockade led to increased shipping costs and delays, impacting the timely delivery of APIs and KSMs to Indian manufacturers. Such disruptions can result in production delays and increased costs for nicotine exporters reliant on these imported materials.

The nicotine export market from India is highly concentrated, with the top five exporters accounting for 92.2% of total exports. Notably, RUBICON RESEARCH PRIVATE LIMITED leads with a 45.8% share, followed closely by B G P HEALTHCARE PRIVATE LIMITED at 41.0%. This high concentration poses a significant single-source risk; any operational or financial issues within these key companies could severely disrupt the supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of APIs and reduce dependency on imports. While this initiative is a positive step, its impact on diversifying the nicotine export market remains to be fully realized.

Geopolitical tensions have recently escalated, notably with the closure of the Strait of Hormuz in March 2026, a critical chokepoint through which approximately 20% of global oil and liquefied natural gas (LNG) transit. This disruption has led to increased shipping costs and delays, affecting the global supply chain, including the pharmaceutical sector.

Additionally, tensions in the Red Sea and the Strait of Hormuz have further complicated shipping routes, leading to rerouting and extended transit times. These disruptions have caused significant delays in the delivery of pharmaceutical products, including nicotine, to key markets such as the United States, which accounts for 90.1% of India's nicotine exports.

• Diversify Supplier Base: Encourage the development of additional nicotine exporters to reduce dependency on a few key players, thereby mitigating single-source risks.

• Enhance Domestic API Production: Accelerate the implementation and expansion of the PLI scheme to bolster domestic manufacturing of APIs and KSMs, reducing reliance on imports.

• Strengthen Supply Chain Resilience: Develop contingency plans, including alternative shipping routes and logistics partnerships, to navigate geopolitical disruptions effectively.

• Monitor Geopolitical Developments: Establish a dedicated team to track and assess geopolitical events that could impact the supply chain, enabling proactive risk management.

• Engage in Strategic Stockpiling: Maintain strategic reserves of critical raw materials and finished products to buffer against supply chain interruptions.

RISK_LEVEL: HIGH